Friday, 23 April 2021

Personal notes about NGS.


In this post, I aim to provide a concise reference guide related to various high-throughput sequencing technologies. I felt compelled to create this guide, as I've often had to refer back to these details and occasionally found it challenging to locate the specific data.

**Sanger Sequencing:**

- **Throughput:** Capable of running up to 384 samples in a single session.
- **Base Reads:** Offers read lengths of approximately 700 base pairs.
- **Daily Output:** Can produce up to 1 million bases per day.
- **Coverage:** Typically provides a 7x coverage of the sequence.

I hope that by compiling this information, I'm helping others who may encounter similar difficulties. Whether you're a seasoned expert or new to the field of high-throughput sequencing, having this information at your fingertips can be a valuable time-saver.

Illumina sequencer: 









Comparison of high-throughput sequencing methods
MethodRead lengthAccuracy (single read not consensus)Reads per runTime per runCost per 1 billion bases (in US$)AdvantagesDisadvantages
Single-molecule real-time sequencing (Pacific Biosciences)
Long-Read
30,000 bp (N50);

maximum read length >100,000 bases[79][80][81]

87% raw-read accuracy[82]4,000,000 per Sequel 2 SMRT cell, 100–200 gigabases[79][83][84]30 minutes to 20 hours[79][85]$7.2-$43.3Fast. Detects 4mC, 5mC, 6mA.[86]Moderate throughput. Equipment can be very expensive.
Ion semiconductor (Ion Torrent sequencing)up to 600 bp[87]99.6%[88]up to 80 million2 hours$66.8-$950Less expensive equipment. Fast.Homopolymer errors.
Pyrosequencing (454)700 bp99.9%1 million24 hours$10,000Long read size. Fast.Runs are expensive. Homopolymer errors.
Sequencing by synthesis (Illumina)MiniSeq, NextSeq: 75–300 bp;

MiSeq: 50–600 bp;

HiSeq 2500: 50–500 bp;

HiSeq 3/4000: 50–300 bp;

HiSeq X: 300 bp

99.9% (Phred30)MiniSeq/MiSeq: 1–25 Million;

NextSeq: 130-00 Million;

HiSeq 2500: 300 million – 2 billion;

HiSeq 3/4000 2.5 billion;

HiSeq X: 3 billion

1 to 11 days, depending upon sequencer and specified read length[89]$5 to $150Potential for high sequence yield, depending upon sequencer model and desired application.Equipment can be very expensive. Requires high concentrations of DNA.
Combinatorial probe anchor synthesis (cPAS- BGI/MGI)BGISEQ-50: 35-50bp;

MGISEQ 200: 50-200bp;

BGISEQ-500, MGISEQ-2000: 50-300bp[90]

99.9% (Phred30)BGISEQ-50: 160M;

MGISEQ 200: 300M;

BGISEQ-500: 1300M per flow cell;

MGISEQ-2000: 375M FCS flow cell, 1500M FCL flow cell per flow cell.

1 to 9 days depending on instrument, read length and number of flow cells run at a time.$5– $120
Sequencing by ligation (SOLiD sequencing)50+35 or 50+50 bp99.9%1.2 to 1.4 billion1 to 2 weeks$60–130Low cost per base.Slower than other methods. Has issues sequencing palindromic sequences.[91]
Nanopore Sequencing
Long-Read
Dependent on library preparation, not the device, so user chooses read length (up to 2,272,580 bp reported[92]).~92–97% single readdependent on read length selected by userdata streamed in real time. Choose 1 min to 48 hrs$7–100Longest individual reads. Accessible user community. Portable (Palm sized).Lower throughput than other machines, Single read accuracy in 90s.
GenapSys SequencingAround 150 bp single-end99.9% (Phred30)1 to 16 millionAround 24 hours$667Low-cost of instrument ($10,000)
Chain termination (Sanger sequencing)400 to 900 bp99.9%N/A20 minutes to 3 hours$2,400,000Useful for many applications.More expensive and impractical for larger sequencing projects. This method also requires the time-consuming step of plasmid cloning or PCR.

Sunday, 11 April 2021

What is more important - the individual privacy right or the wellbeing for society?

During my attendance at the National Information Governance training module, I found myself contemplating how data protection regulations in the UK specifically apply to genetic data. My curiosity was piqued by the potential challenges that UK rules governing the use of such data might pose to legitimate healthcare and research applications. This concern is grounded in the understanding that the sharing of genomic data can profoundly enhance medical research and healthcare delivery. The benefits of genomic data sharing are immense, especially when it comes to clinical geneticists comparing uncertain genetic results with existing databases. This comparative approach can often lead to more precise diagnoses, improved disease management, and consequently, enhanced healthcare services. To continually reap these benefits, it's essential to augment the size and diversity of genomics databases. I must admit that I'm not an expert in this area, but my preliminary reading leads me to conclude that there exists a legal gray zone. Striking the right balance between individual rights and the societal imperative of sharing genetic information seems to be a nuanced challenge. It appears that there's a lack of definitive guidance, with different laboratories interpreting the law in subtly distinct ways. The multifaceted nature of this issue allows for various approaches. Central to the debate is the question of whether we can truly identify a person through genetic data. Personal identifiable data is a double-edged sword: it possesses immense intrinsic value but can also be employed maliciously to discriminate or stigmatize individuals. A critical task is defining what constitutes identifiable versus de-identified data, as the current law makes distinctions based on these categories. For instance, if genetic data is deemed neither confidential nor identifiable, the law may permit more liberal sharing. Regrettably, these challenges are not solely technical in nature. The understanding of this complex issue extends into the realms of politics and philosophy. We must grapple with a profound question: What takes precedence, individual privacy rights or societal wellbeing? The stance taken on this question will have significant ramifications for the future of clinical genetics and my professional development. Furthermore, it's vital to recognize the political dimension to this discourse. Advocates for enhanced data sharing may perceive existing protections, such as anonymization coupled with managed access, as more robust than those primarily concerned with safeguarding individual privacy rights. The stakes in this debate are elevated, as the implications for healthcare and society are far-reaching, contingent upon the vision that is ultimately embraced.